Altimmune posts higher than expected Q3 loss

Altimmune

12/11/2026 12:38

Overview
US biopharma firm's Q3 net loss and loss per share missed analyst expectations
Company ended Q3 with $480 mln in cash, cash equivalents and investments
Higher R&D and G&A expenses driven by clinical trials and compensation costs

Outlook
PERFORMA Phase 3 MASH trial progressing as planned; 52-week topline data readout expected in 2029
End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026
Topline data from RESTORE Phase 2 ALD trial expected in second half of 2027

Result Drivers
CLINICAL TRIAL SPENDING - Co said higher R&D expenses were primarily due to ongoing PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD
COMPENSATION AND PROFESSIONAL SERVICES - Co said higher G&A expenses were mainly due to increased compensation expenses and professional services

Company press release: ID:nGNX3DF8s5

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
Miss
$0.15
$0.14 (9 Analysts)
Q3 Net Loss
Miss
$31.61 mln
$25.48 mln (8 Analysts)
Q3 Income from Operations
Miss
-$35.71 mln
-$28.42 mln (7 Analysts)
Q3 Loss Per Basic Share
 
$0.15
 
Q3 Operating Expenses
 
$35.71 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Altimmune, Inc. is $15.00, about 677.2% above its November 11 closing price of $1.93

Reuters Recommended Reads
Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs
Nov 9 - Trevi Therapeutics Q3 net loss widens on higher R&D costs
Nov 12 - Century Therapeutics Q3 net loss narrows, beats analyst expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)